278 related articles for article (PubMed ID: 28463532)
1. Aspirin and omeprazole for secondary prevention of cardiovascular disease in patients at risk for aspirin-associated gastric ulcers.
García-Rayado G; Sostres C; Lanas A
Expert Rev Clin Pharmacol; 2017 Aug; 10(8):875-888. PubMed ID: 28463532
[TBL] [Abstract][Full Text] [Related]
2. Aspirin Use in Secondary Cardiovascular Protection and the Development of Aspirin-Associated Erosions and Ulcers.
Goldstein JL; Scheiman JM; Fort JG; Whellan DJ
J Cardiovasc Pharmacol; 2016 Aug; 68(2):121-6. PubMed ID: 27002280
[TBL] [Abstract][Full Text] [Related]
3. Long-Term Safety of a Coordinated Delivery Tablet of Enteric-Coated Aspirin 325 mg and Immediate-Release Omeprazole 40 mg for Secondary Cardiovascular Disease Prevention in Patients at GI Risk.
Goldstein JL; Whellan DJ; Scheiman JM; Cryer BL; Eisen GM; Lanas A; Fort JG
Cardiovasc Ther; 2016 Apr; 34(2):59-66. PubMed ID: 26725920
[TBL] [Abstract][Full Text] [Related]
4. Yosprala: A Fixed Dose Combination of Aspirin and Omeprazole.
Veltri KT
Cardiol Rev; 2018; 26(1):50-53. PubMed ID: 29045287
[TBL] [Abstract][Full Text] [Related]
5. PA32540 (a coordinated-delivery tablet of enteric-coated aspirin 325 mg and immediate-release omeprazole 40 mg) versus enteric-coated aspirin 325 mg alone in subjects at risk for aspirin-associated gastric ulcers: results of two 6-month, phase 3 studies.
Whellan DJ; Goldstein JL; Cryer BL; Eisen GM; Lanas A; Miller AB; Scheiman JM; Fort JG; Zhang Y; O'Connor C
Am Heart J; 2014 Oct; 168(4):495-502.e4. PubMed ID: 25262259
[TBL] [Abstract][Full Text] [Related]
6. The budget impact of using enteric-coated aspirin 325 mg + immediate-release omeprazole 40 mg to prevent recurrent cardiovascular events.
Zhang W; Han Y; Fort JG; Schofield D; Tursi JP
J Med Econ; 2017 Jun; 20(6):592-598. PubMed ID: 28145783
[TBL] [Abstract][Full Text] [Related]
7. Effect of baseline gastrointestinal risk and use of proton pump inhibitors on frequency of discontinuation of aspirin for secondary cardiovascular prevention in United kingdom primary care.
Martín Merino E; Johansson S; Nagy P; García Rodríguez LA
Am J Cardiol; 2013 Oct; 112(8):1075-82. PubMed ID: 23831164
[TBL] [Abstract][Full Text] [Related]
8. Usefulness of PA32540 in Protecting the Gastric Layer While Providing Secondary Prevention for Coronary Artery Disease.
Kagolanu D; Sayedy N; Haseeb S; Shah S; Lam P; Munnangi S; Viswanathan P; Stephenson K
Am J Cardiol; 2017 Oct; 120(7):1118-1121. PubMed ID: 28803655
[TBL] [Abstract][Full Text] [Related]
9. [Dilemma between gastroprotection and cardiovascular prevention].
Venerito M; Kandulski A; Malfertheiner P
Dtsch Med Wochenschr; 2010 Nov; 135(44):2193-8. PubMed ID: 20979006
[TBL] [Abstract][Full Text] [Related]
10. Comparison of proton pump inhibitor and histamine-2 receptor antagonist in the prevention of recurrent peptic ulcers/erosions in long-term low-dose aspirin users: a retrospective cohort study.
Chen WC; Li YD; Chiang PH; Tsay FW; Chan HH; Tsai WL; Tsai TJ; Wang EM; Cheng JS; Lai KH
Biomed Res Int; 2014; 2014():693567. PubMed ID: 25295267
[TBL] [Abstract][Full Text] [Related]
11. Review of pharmacokinetic and pharmacodynamic modeling and safety of proton pump inhibitors and aspirin.
Gesheff MG; Franzese CJ; Bliden KP; Contino CJ; Rafeedheen R; Tantry US; Gurbel PA
Expert Rev Clin Pharmacol; 2014 Sep; 7(5):645-53. PubMed ID: 25098174
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of aspirin (325 mg) + omeprazole (40 mg) in treating coronary artery disease.
Sharma T; Bliden K; Chaudhary R; Tantry U; Gurbel PA
Expert Opin Pharmacother; 2017 Jan; 18(1):123-131. PubMed ID: 27937054
[TBL] [Abstract][Full Text] [Related]
13. [Strategy to manage low dose aspirin-induced gastrointestinal injury].
Hiraishi H; Maeda M; Sasai T; Kanke K; Shimada T
Nihon Rinsho; 2011 Feb; 69(2):369-75. PubMed ID: 21387691
[TBL] [Abstract][Full Text] [Related]
14. PA tablets: investigational compounds combining aspirin and omeprazole for cardioprotection.
Bliden KP; Brener M; Gesheff MG; Franzese CJ; Tabrizchi A; Tantry U; Gurbel PA
Future Cardiol; 2013 Nov; 9(6):785-97. PubMed ID: 24180537
[TBL] [Abstract][Full Text] [Related]
15. Aspirin and proton pump inhibitor combination therapy for prevention of cardiovascular disease and Barrett's esophagus.
Peura DA; Wilcox CM
Postgrad Med; 2014 Jan; 126(1):87-96. PubMed ID: 24393755
[TBL] [Abstract][Full Text] [Related]
16. Should prophylactic low-dose aspirin therapy be continued in peptic ulcer bleeding?
Sostres C; Lanas A
Drugs; 2011 Jan; 71(1):1-10. PubMed ID: 21175237
[TBL] [Abstract][Full Text] [Related]
17. Esomeprazole and aspirin fixed combination for the prevention of cardiovascular events.
Sylvester KW; Cheng JW; Mehra MR
Vasc Health Risk Manag; 2013; 9():245-54. PubMed ID: 23696706
[TBL] [Abstract][Full Text] [Related]
18. Omeprazole taken once every other day can effectively prevent aspirin-induced gastrointestinal mucosal damage in rats.
Weng J; Song Y; Kuai D; Dai W; Yao Y; Xu W; Li Y; Fan L; Xu B
BMC Gastroenterol; 2024 May; 24(1):187. PubMed ID: 38811868
[TBL] [Abstract][Full Text] [Related]
19. [Gastric protection and treatment with low-dose aspirin].
Agustí-Escasany A; Vallano-Ferraz A
Med Clin (Barc); 2006 Feb; 126(6):232-3. PubMed ID: 16510098
[No Abstract] [Full Text] [Related]
20. Management of low-dose aspirin and clopidogrel in clinical practice: a gastrointestinal perspective.
Lanas A; Gargallo CJ
J Gastroenterol; 2015 Jun; 50(6):626-37. PubMed ID: 25595209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
